Join Atea Pharmaceuticals for a virtual panel discussion featuring several hepatitis C (HCV) key opinion leaders (KOLs) including:

• Jordan Feld, MD, MPH – University of Toronto, Toronto General Hospital, Canada
• Eric Lawitz, MD – Texas Liver Institute, University of Texas Health San Antonio, US
• Anthony Martinez, MD – University of Buffalo, Erie County Medical Center, US
• Nancy Reau, MD – Rush University Medical Center, Chicago, US

The panel of experts will discuss a wide-range of topics including the current HCV patient population, the importance of early diagnosis and treatment of HCV patients, the test-and-treat model of care, is HCV eradication in North America an achievable goal and what a new optimized HCV therapy could provide for prescribers and patients. Company management will also discuss the HCV commercial market opportunity and the global Phase 3 clinical development program evaluating the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor.

A live question and answer session will follow the formal discussion.